AstraZeneca PLC (AZN)
| Market Cap | 232.35B |
| Revenue (ttm) | 47.61B |
| Net Income (ttm) | 6.33B |
| Shares Out | 3.10B |
| EPS (ttm) | 2.03 |
| PE Ratio | 37.28 |
| Forward PE | 16.31 |
| Dividend | $1.45 (1.94%) |
| Ex-Dividend Date | Feb 22, 2024 |
| Volume | 1,993,714 |
| Open | 75.00 |
| Previous Close | 75.03 |
| Day's Range | 74.59 - 75.16 |
| 52-Week Range | 60.47 - 75.81 |
| Beta | 0.19 |
| Analysts | Buy |
| Price Target | 81.67 (+9.0%) |
| Earnings Date | Apr 25, 2024 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus... [Read more]
Financial Performance
In 2023, AstraZeneca's revenue was $45.81 billion, an increase of 3.29% compared to the previous year's $44.35 billion. Earnings were $5.96 billion, an increase of 81.11%.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for AZN stock is "Buy." The 12-month stock price forecast is $81.67, which is an increase of 9.00% from the latest price.
News
AstraZeneca Shares Jump Most Since 2020
Pascal Soriot, CEO of AstraZeneca, joins the Bloomberg Intelligence to discuss AstraZeneca earnings, along with regulatory and scientific updates. He spoke with Paul Sweeney and Molly Smith on Bloombe...
AstraZeneca CEO talks blowout earnings, global growth, new drugs, and pricing
AstraZeneca shares (AZN) revealed a first-quarter earnings beat on Thursday, posting revenue of $12.68 billion, a 19% year-over-year gain. In addition, the pharmaceutical giant has reiterated its full...
AstraZeneca Gets a Boost From Sales of Its Cancer Drugs
American depositary receipts (ADRs) of AstraZeneca (AZN) traded near their all-time high as the Anglo-Swedish pharmaceutical company had solid first-quarter demand for its cancer drugs.
AstraZeneca tops first-quarter revenue and profit expectations
AstraZeneca CEO Pascal Soriot outlines how the pharma giant's first-quarter results were boosted by demand for its rare blood disorder and oncology drugs.
AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
ROCKVILLE, Md. , April 25, 2024 /PRNewswire/ -- AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innov...
AstraZeneca earnings beat expectations as steady drug sales boost revenues
AstraZeneca plc today, on April 25, announced its earnings report for the first quarter of FY24. Total Revenue increased by 19% to $ 12,679 million, driven by an 18% increase in product sales and cont...
AstraZeneca Earnings, Sales Beat Views
AstraZeneca reiterated its full-year guidance after posting first-quarter core earnings and sales above forecasts.
AstraZeneca CFO on Earnings, US Inflation Reduction Act, China Market
AstraZeneca Chief Financial Officer Aradhana Sarin discusses first-quarter earnings, implications of the US Inflation Reduction Act and the outlook for the company's commercial business in China. She ...
AstraZeneca beats first-quarter revenue, profit estimates
AstraZeneca reported quarterly revenue and profit above market estimates on Thursday, buoyed by resilient demand for its oncology and rare blood disorder drugs.
AstraZeneca --- Q1 2024 results
CAMBRIDGE, United Kingdom--(BUSINESS WIRE)--Q1 Earnings Release (25 April 2024).
Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.
A couple of big-picture trends in biotech could add up to a nice investment opportunity. First, corporate buyouts are back in style.
Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announ...
IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
WILMINGTON, Del.--(BUSINESS WIRE)--Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca's IMFINZI® (durvalumab) in combination with standard-of-care chemotherapy demonstrate...
No Evidence Linking Ozempic And Suicidal Thoughts, EU Says
There is no evidence linking diabetes and weight loss drugs like Ozempic and Wegovy to an increase in suicidal thoughts, the European Union's drug regulator said Friday, the latest findings casting do...
FASENRA approved for treatment of children aged 6 to 11 with severe asthma
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's FASENRA® (benralizumab) is now approved by the US Food and Drug Administration (FDA) for add-on maintenance treatment for patients with severe asthma a...
AstraZeneca unveils dividend hike ahead of CEO pay vote at AGM
AstraZeneca said on Thursday it intends to increase annual dividend for 2024 by 7% to $3.10 per share, betting on strong performance and cash generation on the back of its blockbuster drugs and severa...
Eli Lilly's and AstraZeneca's Former Head of Research Dr. Jan Lundberg Invests in AlzeCure and is Proposed for Election to its Board
STOCKHOLM, SWEDEN / ACCESSWIRE / April 10, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB ("AlzeCure" or "the Company"), a pharmaceutical company that develops candidate drugs for CNS...
ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2+ Solid Tumors.
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Daiichi Sankyo's ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or meta...
US FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors
The U.S. Food and Drug Administration on Friday gave accelerated approval for the expanded use of Daiichi Sankyo and AstraZeneca's drug to treat patients with a type of solid tumor.
AstraZeneca's Imfinzi shows promise in treating aggressive lung cancer
Drugmaker AstraZeneca said on Friday its blockbuster cancer drug Imfinzi showed "significant and clinically meaningful" improvement in the primary goals of a late-stage trial designed for an aggressiv...
Healthy Returns: Weight loss, diabetes drug ad spending tops $1 billion
Drugmakers spent big on ads for weight loss and diabetes drugs such as Wegovy and Ozempic. Meanwhile, the FDA approved the first AI diagnostic tool for sepsis.
Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Daiichi Sankyo's Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US for the treatment of adult pat...
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca's (LSE/STO/Nasdaq: AZN) Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been acce...